Showing results (191-200 of 259) with videos related to

Sort By:
Pageof 26
Urologic Oncology|December 28, 2025
Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancerTsuyoshi Morita, Yutaka Yamamoto, Saizo Fujimoto, et al.
Nature Communications|August 29, 2020
Senolytics prevent mt-DNA-induced inflammation and promote the survival of aged organs following transplantationJasper Iske, Midas Seyda, Timm Heinbokel, et al.
Stem Cells and Development|July 29, 2016
microRNA-145 Mediates the Inhibitory Effect of Adipose Tissue-Derived Stromal Cells on Prostate CancerKiyoshi Takahara, Masaaki Ii, Teruo Inamoto, et al.
Oncotarget|January 5, 2018
The combination of preoperative platelet count and neutrophil lymphocyte ratio as a prognostic indicator in localized renal cell carcinomaTakuya Tsujino, Kazumasa Komura, Atsushi Ichihashi, et al.
International Journal of Clinical Oncology|August 7, 2024
Efficacy of robot-assisted partial nephrectomy compared to conventional laparoscopic partial nephrectomy for completely endophytic renal tumor: a multicenter, prospective studyNobuyuki Hinata, Sae Murakami, Yuzo Nakano, et al.
Urologic Oncology|July 11, 2026
Efficacy and safety of first-line immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients on hemodialysisHidetsugu Takahashi, Wataru Fukuokaya, Takafumi Yanagisawa, et al.
NPJ Precision Oncology|September 17, 2024
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinomaKazuki Nishimura, Kiyoshi Takahara, Kazumasa Komura, et al.
Annals of Surgical Oncology|June 24, 2017
Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to NephrectomyTakuya Tsujino, Kazumasa Komura, Tomohisa Matsunaga, et al.
Cancer Diagnosis & Prognosis|May 11, 2023
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial CarcinomaTeruo Inamoto, Ryo Sato, Yuto Matsushita, et al.
Annals of Surgical Oncology|June 27, 2019
The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in JapanKazumasa Komura, Takeshi Hashimoto, Takuya Tsujino, et al.
Pageof 26